Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Thyrotropin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    11 result(s) found for: Thyrotropin. Displaying page 1 of 1.
    EudraCT Number: 2006-004980-79 Sponsor Protocol Number: 001 Start Date*: 2006-10-10
    Sponsor Name:Medical University of Vienna
    Full Title: Effect of the short –term thyrotropin increase after administration of Recombinant Human Thyrotropin on T lymphocyte cytokine production pattern and bone metabolism in healthy subjects
    Medical condition: This is a healthy volunteers trial. Thyrogen is used in patients with thyroid cancer.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2005-004451-35 Sponsor Protocol Number: MRTSH01505 Start Date*: 2007-03-13
    Sponsor Name:Genzyme Europe BV
    Full Title: Study to Evaluate the Dose, Safety and Effectiveness of Modified-Release Recombinant Human Thyroid Stimulating Hormone (MRrhTSH) When Used in Conjunction with Radioiodine for the Treatment of Multi...
    Medical condition: Nodular goiter are clinically recognizable enlargements of the thyroid gland characterized by excessive growth and structural and or functional transformation of one or several areas within the nor...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10043808 Thyrotropin LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DK (Completed) FR (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-003687-37 Sponsor Protocol Number: BRD/05/83 Start Date*: 2006-07-24
    Sponsor Name:University College London
    Full Title: HiLo: Multicentre randomised phase III clinical trial of high versus low dose radioiodine, with or without recombinant human thyroid stimulating hormone (rhTSH), for remnant ablation following surg...
    Medical condition: Differentiated thyroid cancer (DTC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-001158-33 Sponsor Protocol Number: OZR-2016-34 Start Date*: 2017-07-20
    Sponsor Name:The Rotterdam Eye Hospital
    Full Title: A pilot study towards a therapy with prednisolone encapsulated liposomes for the treatment of Graves’ Orbitopathy with reduced systemic steroid exposure
    Medical condition: Graves' Orbitopathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2017-000742-21 Sponsor Protocol Number: 2017/2527 Start Date*: 2017-07-31
    Sponsor Name:Gustave Roussy
    Full Title: Efficacy of a selective MEK (trametinib) and BRAFV600E (dabrafenib) inhibitors associated with radioactive iodine (RAI) for the treatment of refractory metastatic differentiated thyroid cancer with...
    Medical condition: Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients with RAS or BRAF mutation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016935 Follicular thyroid cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066474 Thyroid cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033701 Papillary thyroid cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004450-27 Sponsor Protocol Number: THYR01605 Start Date*: 2006-05-02
    Sponsor Name:GENZYME
    Full Title: Follow-up of Thyroid Cancer Patients from Study THYR-008-00 Who Received Thyroid Remnant Ablation Using Either the Hypothyroid or the Thyrogen Method
    Medical condition: Follow-up of Thyroid Cancer Patients from Study THYR-008-00
    Disease: Version SOC Term Classification Code Term Level
    6.1 10043738 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000209-35 Sponsor Protocol Number: 7805 Start Date*: 2016-08-24
    Sponsor Name:Newcastle upon Tyne Hospitals NHS Foundation Trust
    Full Title: Adjuvant rituximab – a potential treatment for the young patient with Graves’ hyperthyroidism
    Medical condition: Graves' hyperthyroidism
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-002713-39 Sponsor Protocol Number: Dathyrca 1 Start Date*: 2007-10-23
    Sponsor Name:dept of endocrinology J 106, herlev Hosptial
    Full Title: Quality of life related to recombinant TSH treatment compared to no treatment related to iodine uptake, in patient with thyroid cancer. A double blinded, randomized crossover study. Dathyrca I
    Medical condition: in patients with thyroid cancer (follicular or papillary), injektion with recombinant TSH to increase s-TSH before iodine uptake to detect remaining cancer og recurrence of cancer in patients surg...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033701 Papillary thyroid cancer LLT
    9.1 10016935 Follicular thyroid cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-002877-30 Sponsor Protocol Number: CSOM230B2212 Start Date*: 2006-12-22
    Sponsor Name:NOVARTIS FARMA
    Full Title: An open label, multicenter, pilot phase II study of SOM230 s.c. in patients with duodeno-pancreatic (neuro) endocrine tumors and different pituitary diseases (Nelsonﾒs syndrome, non-functioning ad...
    Medical condition: duodeno-pancreatic (neuro) endocrine tumors and different pituitary diseases (Nelsonﾒs syndrome, non-functioning adenoma, TSH-adenoma,Gonadotroph adenoma, and PRL-adenoma)
    Disease: Version SOC Term Classification Code Term Level
    6.1 10035098 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002952-34 Sponsor Protocol Number: NN9924-4437 Start Date*: 2020-09-07
    Sponsor Name:Novo Nordisk A/S
    Full Title: Efficacy and safety of oral semaglutide versus placebo both in combination with metformin and/or basal insulin in children and adolescents with type 2 diabetes
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) PT (Trial now transitioned) GR (Trial now transitioned) NL (Trial now transitioned) AT (Trial now transitioned) BE (Completed) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-020855-29 Sponsor Protocol Number: E1496/09 Start Date*: 2009-10-16
    Sponsor Name:UNIVERSITA' DEGLI STUDI DI MESSINA
    Full Title: Radioiodine ablation of post-surgical thyroid remnants by recombinant human TSH (rhTSH) in patients with moderately severe and severe Graves' orbithopathy (GO)
    Medical condition: Patients affected with moderately severe and severe GO
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10015919 Eye disorders SOC
    14.1 10014698 - Endocrine disorders 10043739 Thyroid gland disorders HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 10:46:04 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA